Befejeződött1. fázis
A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
A legfontosabb adatok
- Ki végzi
- Phathom Pharmaceuticals, Inc.
- Hol
- Atlanta, Dayton, El Paso, Frisco, Gresham, Hollywood, Indianapolis, Little Rock, Marrero, Mobile, Pensacola, Tampa és The Bronx (Egyesült Államok)Mind a 13 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 1. fázis
- Résztvevők
- 22 fő vett részt
- Kezdés
- 2023. nov. 1.
- Befejezés
- 2024. ápr. 29.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Vonoprazan
- A regiszteradat frissítve
- 2024. december 19.
Ki vehet részt
- Életkor
- 6 év – 11 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- The participant has a body weight within the 5th through 95th percentile by age, inclusive, as determined by the National Center for Health Statistics
- The participant must have a diagnosis of GERD prior to randomization and medical history of signs or symptoms of GERD for at least 3 months prior to screening, based on physical examination, current symptoms (eg, heartburn), or diagnostic tests (eg, pH or endoscopy). Notes in the medical records and/or other source documents, such as prior endoscopies, can be used to support the diagnosis and will be recorded in the electronic case report form (eCRF)
- The participant has at least one moderate GERD symptom based on the GERD Symptom Assessment Investigator scale performed at screening
- The participant must be able to swallow study drug tablet with water
- Parent or legal guardian (ie, legally authorized representative [LAR]) is willing and able to complete the informed consent process and participants are able to comply with study procedures and visit schedule
- Female participants who have experienced menarche must have a negative pregnancy test and will be counseled on pregnancy avoidance
Ki nem vehet részt
- The participant has used prescription or non-prescription proton pump inhibitors (PPIs) or histamine-2 receptor antagonist (H2RAs) within 7 days prior to randomization or requires use during the Treatment Period
- The participant has used sucralfate, or antacids within 1 day prior to randomization or requires their use during the Treatment Period
- The participant has received other agents affecting digestive organs, including muscarinic antagonists (eg, hyoscyamine), prokinetics, oral anticholinergic agents, prostaglandins, bismuth from 30 days prior to Day 1 or requires their use during the course of the study
- The participant has received atazanavir sulfate or rilpivirine hydrochloride from 5 days prior to Day 1 or requires their use during the course of the study
- The participant has received any investigational compound (including vonoprazan) within 30 days prior to the start of the Screening Period
- The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Period
- The participant has undergone prior gastrointestinal surgeries
- The participant has used any prescription or over-the-counter medications (including herbal or nutritional supplements), other than those already excluded in criteria 1 to 5 above, within 14 days before the first dose of study drug or throughout the study. That is, unless the medication(s) is permitted by the sponsor following a review of available data which confirms concomitant administration of the medication is unlikely to affect either the safety of the participant or the pharmacokinetics of vonoprazan
- The participant has consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days (or 5 half-lives) before the first dose of study drug or throughout the study
- The participant has positive results at screening for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus (HCV)
- The participant has severe renal impairment (estimated glomerular filtration rate < 30 mL/min)
- The participant has moderate to severe hepatic impairment (Child-Pugh Class B and Child-Pugh Class C)
- The participant has any abnormal laboratory test values that are considered clinically significant in the opinion of the investigator during the Screening Period
- The participant has a history of hypersensitivity or allergies to vonoprazan (including the formulation excipients: D-mannitol, microcrystalline cellulose, hydroxypropylcellulose, fumaric acid, ascorbic acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, and titanium dioxide, or red or yellow ferric oxide)
- The participant has any of the following abnormal laboratory test values at the start of the Screening Period:; Creatinine levels: >0.8 mg/dL (>70 μmol/L); Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 × the upper limit of normal (ULN) or total bilirubin >2 × ULN (except participants with Gilbert Syndrome)
- The participant is an immediate family member or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, child, sibling) or participant may have consented under duress
- In the opinion of the investigator, the participant is not suitable for entry into the study
Helyszínek itt: Egyesült Államok
- Children's Center for Digestive Health Care, LLCAtlanta, Egyesült Államok
- Primed Clinical ResearchDayton, Egyesült Államok
- Maspons Pediatric GastroEl Paso, Egyesült Államok
- Stryde Research - NxT Step PediatricsFrisco, Egyesült Államok
- Cyn3rgy ResearchGresham, Egyesült Államok
- Med Research Associates, IncHollywood, Egyesült Államok
- Riley Hospital for Children at IU HealthIndianapolis, Egyesült Államok
- Preferred Research Partners, IncLittle Rock, Egyesült Államok
- Tandem Clinical Research GI, LLCMarrero, Egyesült Államok
- Strada Patient Care CenterMobile, Egyesült Államok
- Avanza Medical Research CenterPensacola, Egyesült Államok
- International Center for ResearchTampa, Egyesült Államok
- Advantage Clinical TrialsThe Bronx, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20 mg once daily [QD]) in children ≥ 6 to < 12 years of age who have symptomatic Gastroesophageal Reflux Disease (GERD).
A vizsgálat 2 csoportja
- Vonoprazan 10mgA vizsgált kezelés
Participants will receive vonoprazan 10mg QD for 14 days.
Kezelés: Vonoprazan
- Vonoprazan 20mgA vizsgált kezelés
Participants will receive vonoprazan 20mg QD for 14 days.
Kezelés: Vonoprazan
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Children Aged ≥ 6 to < 12 Years Who Have Symptomatic Gastroesophageal Reflux Disease
- A regiszteradat frissítve
- 2024. december 19.